Antibiotic Resistance: Is Pharma Doing Enough?

Developed resistances to certain antibiotics have occurred since their creation in the 1940s. Scientists found the first case of resistance just four years after antibiotics entered mass production. Only recently, however, has the issue taken a critical turn. Resistant strains of...

1 month ago
R&D,Pharmacovigilance,Biology

Antibiotic Resistance: Is Pharma Doing Enough?

Developed resistances to certain antibiotics have occurred since their creation in the 1940s. Scientists found the first case of resistance just four years after antibiotics entered mass production. Only recently, however, has the issue taken a critical turn. Resistant strains of...

1 month ago

AI and Pharmacovigilance ADR processing

Many of the problems that have long been inherent in Pharmacovigilance (PV) - such as historic limitations in the information that is published in case reports, analysis of electronic health records and integration - have found an answer in the...

5 months ago
R&D,Pharmacovigilance,Bioinformatics

AI and Pharmacovigilance ADR processing

Many of the problems that have long been inherent in Pharmacovigilance (PV) - such as historic limitations in the information that is published in case reports, analysis of electronic health records and integration - have found an answer in the...

5 months ago

The Abbvie-Allergan Deal: A Matter of Distrust?

Compared to the merger announcement itself, the industry reaction to the $63 billion Abbvie buyout of Allergan, announced this June, was no big surprise. Abbvie, seeking to replace its now-ageing blockbuster drug Humira, was the only suitor for the Botox...

5 months ago
Pharmacovigilance,News

The Abbvie-Allergan Deal: A Matter of Distrust?

Compared to the merger announcement itself, the industry reaction to the $63 billion Abbvie buyout of Allergan, announced this June, was no big surprise. Abbvie, seeking to replace its now-ageing blockbuster drug Humira, was the only suitor for the Botox...

5 months ago